Impact of Exercise Capacity Upon Respiratory Functions, Perception of Dyspnea, and Quality of Life in Patients with Chronic Obstructive Pulmonary Disease

Wenjun Liu1,2
Yufei Liu1,2
Xiaolin Li1,2

1Department of Human Movement Science in Graduate School, Harbin Sport University, Harbin, 150000, People’s Republic of China; 2Department of Sports Science and Health, Harbin Sport University, Harbin, 150000, People’s Republic of China

Background: Chronic obstructive pulmonary disease (COPD) is associated with a high prevalence of morbidity and mortality worldwide. We investigated the effects of exercise capacity upon respiratory functions, perception of dyspnea, and quality of life (QoL) in patients with COPD.

Methods: A total of 512 COPD patients formed the study cohort. They were divided into four subgroups according to the distance walked in the 6-minute walking test (6MWT). We compared respiratory functions, perception of dyspnea, and QoL between groups.

Results: Patients who walked >350 m had significantly better disease-specific QoL scores (p < 0.001) than those of other groups. A negative correlation was found between the walking distance and anxiety, depression, and dyspnea scores (p < 0.001).

Conclusions: In patients who walked <350 m, the reduced walking distance adversely affected respiratory functions, psychological symptoms, and QoL.

Keywords: chronic obstructive pulmonary disease, exercise, quality of life, statistics

Introduction

Chronic obstructive pulmonary disease (COPD) is a prevalent disease worldwide and leads to a high prevalence of morbidity and mortality.1 It is characterized by irreversible, progressive airflow limitation, and repeated airway inflammation, which seriously affects the quality of life (QoL) of patients with COPD.2 Environmental factors and genetic mutations have roles in COPD. Exposure to cigarette smoking, occupational exposure to chemicals, and environmental pollution are risk factors for COPD.3 Furthermore, several studies have shown that genetic factors are involved in COPD pathogenesis.4 Dyspnea is an important contributor to QoL decline.5 The clinical symptoms of COPD also include sputum production, chronic cough, and wheezing. COPD is the fourth leading cause of death worldwide.6 Reduced activity due to dyspnea can also cause psychological problems (eg, anxiety, depression).7

The diagnosis of COPD is established through spirometry. A ratio of post-bronchodilator forced expired volume in one second/forced vital capacity (FEV1/FVC) <0.7 denotes persistent airflow obstruction.8 However, spirometry values are usually not a good predictor of QoL in patients with COPD, and also correlate...
weakly with dyspnea, exercise capacity, and health status.\textsuperscript{9}  Therefore, we can measure the impact of chronic diseases and treatment efficacy by assessing QoL.\textsuperscript{10}  Functional evaluations, such as assessment of exercise capacity, are useful tools. The 6-minute walk test (6MWT) can be used to measure exercise capacity.\textsuperscript{11}  Several concomitant physiological variables, such as heart rate, workload, and oxygen consumption, can be monitored. At least partly due to systemic inflammation, extrapulmonary symptoms and anemia may occur, such as cachexia.\textsuperscript{12}  COPD can be treated first by removal/modification of risk factors (eg, smoking cessation). Exercise training, typically to a pulmonary rehabilitation program, is efficacious treatment in COPD patients in terms of exercise capacity and health-related QoL.\textsuperscript{13}  Studies have shown that COPD and its consequent daily activity restrictions affect QoL.\textsuperscript{14}  Exercise ability can be reflected by exercise tests. However, the extent to which exercise testing accurately reflects QOL as assessed by clinical parameters is not clear. At present, there are few studies on the detailed and comprehensive analysis of the effect of exercise capacity on the clinical parameters of COPD patients.\textsuperscript{15,16}  In this study, we wished to investigate the effects of exercise capacity on respiratory functions, perception of dyspnea, and QoL in patients with COPD. We used only the BODE Index as a reference for grouping of COPD patients. In this way, we could more clearly examine the impact of reducing the walking distance on patients with COPD. And reducing walking distance has a negative effect on the clinical indicators of COPD patients.

Methods

Ethical Approval of the Study Protocol

The study was conducted in accordance with the Declaration of Helsinki. The study protocol was approved by Graduate School of Harbin Sport University. The purpose of the assessment methods was detailed to patients. Written informed consent was obtained from all participants.

Characteristics of Patients

Demographic and clinical characteristics (eg, smoking history) were recorded. Pulmonary function tests, chest radiography, and arterial blood gases (ABG) were evaluated.

Bode Index

The BODE Index is a multidimensional grading system comprising the body mass index (BMI), airway obstruction, dyspnea scale, and exercise capacity. It is being used increasingly for COPD evaluation. The BODE Index is calculated based on the combination of four variables for each patient with COPD. The calculation rules are the evaluation score of the: (i) body composition (BMI): from 0 point to 1 point; (ii) intensity of airflow obstruction (FEV\textsubscript{1}/% predicted post-bronchodilator): from 0 point to 3 points; (iii) subjective sensation of dyspnea (Medical Research Council (MRC) scale): from 0 point to 3 points; (iv) exercise capacity (walked distance in the 6MWT): from 0 point to 3 points. Therefore, the total score of the BODE Index ranges from 1 to 10. The closer the BODE Index score is to 10, the more severe is the condition. According to the 6MWT, patients with COPD can be divided into four groups: 1 (walked <150 m); 2 (walked between 150 m and 249 m); 3 (walked between 250 m and 349 m); 4 (walked ≥350 m). The reason for this grouping is to be able to more clearly examine the impact of reduced walking distance on COPD patients and follow-up statistical analysis. In addition, our grouping system also used the BODE Index as a reference. All parameters were compared again between these four groups.

Pulmonary Function

Body plethysmography was undertaken using a Zan 500 system (Belgium). Carbon-monoxide diffusion capacity (TLCO) was measured using a Zan 300 system. Patients had to meet a postbronchodilator ratio of FEV\textsubscript{1}/FVC <0.7.

Evaluation of Dyspnea

Dyspnea severity was determined using the MRC dyspnea scale. A score of 1 was considered to denote perception of the mildest dyspnea. A score of 5 denoted perception of the most severe dyspnea.

QoL

The Saint George’s Respiratory Questionnaire (SGRQ) was used to assess disease-specific QoL. The higher the score, the worse the disease, and an increase in symptoms was likely.

Psychological Symptoms

The Hospital Anxiety and Depression (HAD) scale was used to determine mental status. There are 14 questions in the HAD scale. A score for anxiety and depression of 0–7 is “normal”, 8–11 is “borderline” and >11 indicates “anxiety or depression”.

\textsuperscript{9}  Liu \textsuperscript{10}  Press
Exercise Capacity
The 6MWT was employed to determine exercise capacity. Patients were asked to walk as fast as they could for 6 min, and the result was measured in meters. If the test result does not meet the requirements, multiple repeat tests can be undertaken. 17

Statistical Analyses
Statistical analyses were undertaken using SPSS 20.0 (IBM, Armonk, NY, USA). The normality of the data distribution was checked by the Shapiro–Wilk test and Kolmogorov–Smirnov test. If the data distribution was not normal, continuous variables were expressed as the median (interquartile range) and categorical variables as percentages. Fisher’s exact test was used for variables determined with numbers. The Kruskal–Wallis H-test was conducted to compare data between groups. The Mann–Whitney U-test was employed to test the significance of pairwise differences. The Bonferroni correction was undertaken to adjust for multiple comparisons. p < 0.05 was considered significant.

Results
The demographic and clinical characteristics of 512 COPD patients are shown in Table 1. Except for sex, the other parameters tested were significantly different (p < 0.001 for all). The age of group-4 patients was significantly lower than that of patients in the other three groups (p < 0.001). BMI was significantly higher in group 4 than that in groups 1 (p = 0.035) and group 2 (p = 0.012). BMI of group 3 was significantly higher than that of group 1 (p = 0.041). The number of cigarettes consumed between group 1 and group 2 was comparable. Compared with the other three groups, the number of admissions to the emergency department and hospitalization within the previous year was significantly lower in group 4 (p < 0.001). According to admissions to the emergency department, the number was lower in group 3 (p = 0.021) and group 2 than those for group 1 (p = 0.035). FEV1 (%) and FEV1/FVC were comparable between group 1 and group 2, but significantly higher in group 4, compared with those in all other groups, and significantly higher in group 3 compared with those in group 1 and group 2 (p < 0.005). TLCO was comparable between group 1 and group 2, but significantly higher in group 4 compared with that in all other groups (p < 0.001), and significantly higher in group 3 compared with that in group 1 (p = 0.040) and group 2 (p = 0.035). Measurement of ABGs revealed that the partial pressure of oxygen (PaO2) and arterial oxygen saturation (SaO2) were significantly higher in group 4 compared with those in all other groups (p < 0.001). Comparison between group 1

Table 1 Demographic and Clinical Characteristics of the Patients

| Variables (n = 512) | Group 1 (n = 38) | Group 2 (n = 54) | Group 3 (n = 135) | Group 4 (n = 285) | P |
|---------------------|-----------------|-----------------|------------------|------------------|---|
| Age (years)         | 67(63,71)       | 66(61,71)       | 65(60,69)        | 61(53,67)        | <0.001* |
| Body Mass Index (kg/m2) | 25(21,29)     | 25(21,28)      | 26(23,30)        | 27(23,31)        | 0.022*  |
| Male gender n (%)   | 33(86.8)        | 43(79.6)        | 111(82.2)        | 225(78.9)        | 0.920*  |
| Cigarette consumption (p/year) | 68(45,90) | 60(40,88)     | 55(40,80)        | 50(30,75)        | 0.002*  |
| Emergency admission (n/last 1 year) | 2(1,5)          | 2(0,6)          | 1(0,4)           | 0(0,1)           | <0.001* |
| Hospital admission (n/last 1 year) | 1(0,2)          | 1(0,2)          | 0(0,1)           | 0(0,0)           | <0.001* |
| PFT                 |                 |                 |                  |                  |      |
| FEV1 (%)            | 26(22,40)       | 32(24,45)       | 38(30,55)        | 54(39,68)        | <0.001* |
| FEV1/FVC (%)        | 47(43,58)       | 51(44,66)       | 57(50,65)        | 65(54,72)        | <0.001* |
| TLCO (%)            | 28(18,37)       | 26(17,38)       | 34(22,50)        | 45(33,60)        | <0.001* |
| ABG                 |                 |                 |                  |                  |      |
| PaO2 (mmHg)         | 65(56,77)       | 65(55,76)       | 72(62,80)        | 78(71,85)        | <0.001* |
| SatO2 (%)           | 92(88,96)       | 94(90,95)       | 94(92,95)        | 96(94,99)        | <0.001* |
| 6 MWD (meter)       | 120(80,145)     | 200(180,215)    | 310(280,325)     | 424(380,450)     | <0.001* |

Notes: Data are performed as median (interquartile range) or percentile (%). *Kruskal Wallis Test; **Chi Square Test. Group 1, six minute walk distance is less than 150 m; group 2, six minute walk distance is between 150 and 249 m; group 3, six minute walk distance is between 250–349 m; group 4, six minute walk distance is greater than 350 m.

Abbreviations: BMI, body mass index; PFT, pulmonary function test; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; TLCO, carbon-monoxide diffusion capacity; ABG, arterial blood gases; PaO2, partial arterial oxygen pressure; SaO2, arterial oxygen saturation; 6MWD, 6-min walk distance.
Table 2 Comparison of Dyspnea, Quality of Life, Anxiety, and Depression Among the Groups

| Variables | Group 1 (n = 39) | Group 2 (n = 54) | Group 3 (n = 137) | Group 4 (n = 286) | P |
|-----------|-----------------|-----------------|-------------------|-------------------|---|
| MRC       | 5(4.5)          | 5(4.5)          | 4(4.3)            | 3(2.3)            | <0.001* |
| SGRQ      |                 |                 |                   |                   |   |
|   Symptom | 72(56.78)       | 65(51.77)       | 59(45.71)         | 52(43.73)         | <0.001* |
|   Activity| 87(75.100)      | 86(69.93)       | 75(60.86)         | 56(43.75)         | <0.001* |
|   Effect  | 65(50.78)       | 62(45.76)       | 54(40.70)         | 40(26.53)         | <0.001* |
|   Total   | 74(59.81)       | 65(60.77)       | 61(48.73)         | 50 (34.59)        |   |
| HAD       |                 |                 |                   |                   |   |
|   Anxiety | 10(6.17) 9(6.11)| 9(6.16)         | 9(5.13)           | 6(4.9)            | <0.001* |
|   Depression| 10(6.17) 9(6.11)| 9(5.11)         | 7(5.12)           | 5(3.9)            | <0.001* |

Notes: Data are expressed as median (interquartile range); *Kruskal–Wallis test. Group 1, six minute walk distance is less than 150 m; group 2, six minute walk distance is between 150 and 249 m; group 3, six minute walk distance is between 250–349 m; group 4, six minute walk distance is greater than 350 m.

Abbreviations: MRC, Medical Research Council Dyspnea Scale; SGRQ, St. George’s Respiratory Questionnaire; HAD, Hospital Anxiety and Depression Scale; IQR, interquartile range.

and group 2 revealed PaO₂ (p = 0.045) and SaO₂ to be significantly higher than those in group 3 (p = 0.022).

The perception of dyspnea was lower in group 4 compared with that in all other groups (p < 0.001) and it was significantly lower in group 3 compared with that in group 1 (p = 0.022) and group 2 (p = 0.035). Dyspnea scores were comparable between groups 1 and 2 (p = 0.561).

With regard to SGRQ scores, the symptom score, activity score, and effect score were significantly lower in group 4 compared with those in all other groups (p < 0.001). The total score in group 4 was significantly lower compared with that in the other three groups (p < 0.001).

Table 2

Discussion

We divided COPD patients into four groups based on the distance walked in the 6MWT. We found that the walking distance had a correlation with smoking, BMI, and age. As patients smoked more and became older, BMI decreased and patients walked shorter distances. A reduced walking distance also meant higher numbers of admissions to the emergency department and hospitalization during the previous year. Patients who had shorter walking distances had a higher perception of dyspnea and their psychological symptoms increased, which led to lower QoL.

Impact of Exercise Capacity Upon Respiratory Functions in Patients with COPD

COPD is characterized by airflow obstruction that is partially reversible. COPD not only causes an abnormal inflammatory response in the lungs, it also reduces exercise capacity.18 People who smoke are more likely to suffer from COPD than people who do not smoke, with 20–25% of smokers going on to develop COPD.19 The prevalence of COPD in people aged >40 years is higher than that in individuals aged <40 years, and is not related to sex.20 The FEV₁ of patients with COPD decreases gradually as the disease progresses. The diagnosis is established through spirometry, so the FEV₁ measurement can play an important part, but it cannot fully reflect the adverse effects of COPD.

Exercise capacity is a very important parameter to measure COPD. Recently, it has been used to evaluate the prognosis and the effect of therapeutic interventions.21 The 6MWT is usually employed for assessment of the functional status of patients. The walking distance will decrease gradually over time, but it is not associated with respiratory function.22 In our study, the average age of COPD patients who walked >350 m was significantly lower than that of the other patients. For patients who walked >350 m, the FEV₁, FEV₁/FVC, and TLCO in the respiratory function test also increased significantly. Studies have reported that the distance walked in the 6MWT is linearly related to COPD severity.23 In the present study, patients with a walking distance <150 m had significantly more severe COPD than that of other patients. Consistent with a study reporting a negative correlation between smoking and exercise capacity,24 most of our patients who consumed more cigarettes walked a shorter distance. We found that the BMI of patients who walked ≥350 m was significantly higher than that of the other groups: this result is consistent with the research results of Punekar and colleagues.9 The walking distance of COPD patients
was significantly longer after presenting to the emergency department. Studies have shown that hospital admission reduces walking distances significantly, and there is a negative correlation between walking distances and the number of hospital admissions. In our study, the number of emergency hospital admissions and hospitalizations was significantly negatively correlated with the walking distance.

Impact of Exercise Capacity Upon Perception of Dyspnea with COPD
As one of the main symptoms of COPD, dyspnea can lead to decreased activities of daily living (ADL), physical deterioration, and exercise intolerance. Other studies have shown that the improvement of physical activity can make the patient’s lung function slightly better, less dyspnea, and better quality of life. A negative correlation between the walking distance and perception of dyspnea has been documented. In our study, the perception of dyspnea was significantly lower in patients whose walking distance was >350 m (ie, the walking distance decreased with an increase in perception of dyspnea). COPD also has a negative impact on a patient’s psychology and brings a heavy burden to society. Patients with COPD are confronted with social isolation and psychological symptoms due to reduced ADL. In the present study, the scores for anxiety and depression (the most common physical symptoms of COPD patients) increased significantly as the walking distance increased.

Impact of Exercise Capacity Upon Quality of Life in Patients with COPD
The QoL of COPD patients worsens and their exercise capacity decreases with time. Smoking, psychological symptoms, dyspnea, and decreased ADL lead to a decline in the QoL of patients. In sub-scores of the SGRQ, “activity” and “effect” scores have been shown to be negatively correlated with walking distance. We found a negative correlation between the SGRQ score and walking distance. Patients who walked >350 m had a significantly lower SGRQ score (sub-scores and the total score) than that for patients in the other groups.

Table 2
With regard to the limitations of our study, we did not consider other influencing factors (eg, economic status, marriage, profession). Moreover, medication alone is not enough for COPD patients. Therefore, in the treatment plan for COPD, in addition to drug treatment, attention should also be paid to increasing walking distance, providing nutrition and psychological support, and improving the quality of life.

Conclusions
COPD patients were divided into four groups according to the walking distance. Patients who walked >350 m were significantly younger, had higher BMI, smoked less, and had better respiratory functions and oxygenation compared with those in the other groups. We discovered a negative correlation between the walking distance and dyspnea, psychological symptoms, and QoL. The shorter the distance the patient walked, the higher number of admissions to the emergency department and hospitalization. Increasing the walking distance, relieving dyspnea, smoking less, and improving QoL are very important parameters for the recovery of patients with COPD.

Acknowledgments
Special thanks to Xiao Lanlu for helping us with patient communication, patient privacy, etc.

Disclosure
The authors report no conflicts of interest in this work.

References
1. Wang N, Wang Q, Du T, et al. The potential roles of exosomes in chronic obstructive pulmonary disease. Front Med. 2020;7:618506. doi:10.3389/fmed.2020.618506
2. Putcha N, Puhon MA, Hansel NN, Drummond MB, Boyd CM. Impact of co-morbidities on self-rated health in self-reported COPD: an analysis of NHANES 2001–2008. Cogd. 2013;10(3):324–332. doi:10.1109/3109.15412555.2012.744963
3. Soriano JB, Abajobir AA, Abate KH, et al. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Respir Med. 2017;5(9):691–706. doi:10.1016/s2213-2600(17)30293-x
4. Hobbs BD, Hersh CP. Integrative genomics of chronic obstructive pulmonary disease. Biochem Biophys Res Commun. 2014;452(2):276–286. doi:10.1016/j.bbrc.2014.07.086
5. Nici L, Donner C, Wouters E, et al. American thoracic society/ European respiratory society statement on pulmonary rehabilitation. Am J Respir Crit Care Med. 2006;173(12):1390–1413. doi:10.1164/rccm.200508-1211ST
6. Hashemi SY, Momenabadi V, Faramarzi A, Kiani A. Trends in burden of chronic obstructive pulmonary disease in Iran, 1995–2015: findings from the global burden of disease study. Arch Public Health. 2020;78:45. doi:10.1186/s13690-020-00426-x
7. Bowers S, Cannizzaro K, Gregus J, Scott Q, Eason J. Outcomes in cardiopulmonary physical therapy: sickness impact profile. Cardiopulm Phys Ther J. 2009;20(1):19–24. doi:10.1097/01823246-200920010-00004
Publish your work in this journal

The International Journal of Chronic Obstructive Pulmonary Disease is an international, peer-reviewed journal of therapeutics and pharmacology focusing on concise rapid reporting of clinical studies and reviews in COPD. Special focus is given to the pathophysiological processes underlying the disease, intervention programs, patient focused education, and self management protocols. This journal is indexed on PubMed Central, MedLine and CAS. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is entirely computerized for speed and efficiency.

Submit your manuscript here: https://www.dovepress.com/international-journal-of-chronic-obstructive-pulmonary-disease-journal